arGEN-X announces collaboration with Bayer to discover and develop therapeutic antibody candidates

02-Jun-2014 - arGEN-X announced the initiation of a collaboration with Bayer Pharma AG (Bayer), leveraging arGEN-X’s SIMPLE Antibody™ technology for the discovery and development of therapeutic antibodies. The collaboration centers on a novel approach to addressing complex targets across multiple therapeutic ...

Gecko Biomedical receives RadTech’s Emerging Technology Award

20-May-2014 - Gecko Biomedical announced that it has received the prestigious “RadTech’s Emerging Technology Award” at RadTech 2014, RadTech’s annual technology conference. Gecko Biomedical is developing a platform of biocompatible, biodegradable adhesive solutions specifically designed for minimally invasive ...

Heptares describes Class B GPCR strucutre

Unique structural insights from CRF1 structure will drive drug discovery programmes targeting important Class B GPCRs including GLP1 (diabetes)

19-Jul-2013 - Heptares Therapeutics announces the publication of a scientific article describing the high resolution X-ray crystal structure of the corticotropin-releasing factor receptor 1 (CRF1) receptor in Nature.CRF1 is the receptor for the hormone CRF, which is important in regulating the body’s response ...

OBN announces changes to board of directors

17-Jan-2013 - OBN announced changes to the OBN Board of Directors. Dr Steven Lee is reluctantly standing down as Chairman and his place will be taken by David Laskow-Pooley. Congratulating David on his appointment Steven said that “after 6 years as Chairman and with my business interests becoming increasingly ...

Heptares partners with cubist to research new medicines targeting GPcrs

10-Jan-2013 - Heptares Therapeutics announced they have signed an agreement with Cubist Pharmaceuticals, Inc. to collaborate on the research and discovery of new medicines targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and ...

Prosonix receives Grant Award from the Biomedical Catalyst to accelerate development of multi-component particle

09-Jan-2013 - Prosonix has received a grant worth up to £1.3M from the Biomedical Catalyst. The grant will provide matched-funding support for the pre-clinical development of the Company’s Multi-component particle™ (MCP™) platform as a basis for future combination respiratory medicines. The £180M Biomedical ...

arGEN-X initiates Phase Ib study of ARGX-110 in cancer

08-Jan-2013 - arGEN-X announced the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody™ program to enter the clinic in just three years from initiation of discovery. ARGX-110 is a first-in-class CD70-targeting monoclonal antibody that addresses both known mechanisms of ...

Elacytarabine in combination with idarubicin shows promising efficacy in Phase II trial in acute myeloid leukaemia

14-Dec-2012 - Clavis Pharma ASA announces data from its Phase II clinical trial with elacytarabine in combination with idarubicin. The trial enrolled patients with early stage acute myeloid leukaemia (AML), for whom cytarabine-containing first-course chemotherapy has failed. The results found that treatment ...

Prosonix Elects Dr Ken Cunningham as Non-executive Chairman

07-Dec-2012 - Prosonix announced the election of Dr Ken Cunningham as Non-executive Chairman. He replaces Dr Jim Philips, who has been Chairman of the Company since 2007, and is retiring from the Board of Directors.Dr Cunningham was elected to the Board of Prosonix as a Non-executive Director in September ...

Heptares provides Gpcr expertise to new European drug discovery consortium

Consortium supported with over €20 million funding from EU Innovative Medicines Initiative and big pharma

04-Dec-2012 - Heptares Therapeutics is joining a group of European academic and industry researchers known as the ‘K4DD’ (‘Kinetics for Drug Discovery’) Consortium to investigate binding kinetics or ‘kinotypic’ properties of drug-receptor complexes. The five-year program will focus on important drug target ...